Dry age-related macular degeneration (AMD) is a chronic neurodegenerative disease that can eventually lead to blindness and cellular senescence of the retinal pigment epithelium (RPE) RPE cells are thought to be an important mediator in the pathogenesis of macular degeneration. Israeli scientist Ayala Pollack and his team have investigated a novel minimally invasive therapy for AMD that affects aging RPE cells using a new compound that specifically interferes with the metabolism of senescent cells and reduces aging phenotypes and complications, thereby acting as a delaying factor for AMD development. It has now been validated in in-vitro and in animal model tests.